ESMO 2025: Sichuan-Kelun Enters Breast Cancer ADC Space
The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in other markets.
Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway.
On 18 October 2025, the OptiTROP-Breast02 trial was presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
Sichuan Kelun-Biotech presented findings from their Phase III trial, which compared sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, with physician’s choice of chemotherapy in metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2) breast cancer (BC) patients.
No direct quotes available in the text.
Author’s summary: Sichuan-Kelun enters breast cancer ADC space with sac-TMT.